As we've often celebrated, one of the best shipway to find out what's new and hot in diabetes applied science is to follow the industry's "earnings calls" — those time period webcasts designed to update investors connected predicted product pipelines and business flow in the months forward. These calls also offer the States patients a sneak peek into what we can expect down the road.

With the end of the first one-fourth approaching at the end of March, the self-aggrandising diabetes tech companies are presently updating investors on their CRO of business from the other yr and what they wear tap for 2017. Quite an heap of interesting tidings came out of calls finished the past few weeks by Tandem Diabetes Wish, Medtronic, Dexcom, Insulet and others.

Here's a rundown of what we noninheritable by listening in:

In tandem Diabetes Care

Anyone obstructed in to the financial side of Tandem Diabetes knows business isn't good these days for the California insulin ticker company, which forward brought us the novel touchscreen t:slim pump five years ago.

Business woes stimulate been plaguing the party for months and Tandem's been trying to bring in gross all the same it can, including a March 1 filing with the SEC for a follow-up public offering aimed at garnering more money. It's also not a good sign when a company files with the SEC notice that IT's going to pay cash bonuses to two top execs to stay with the company end-to-end the spring and summer.

Speculation is swirling about how long Tandem can last and whether a buyout mightiness be coming sooner rather than later, but right now nothing's authoritative.

In the meantime, Bicycle-built-for-two continues bright that it has big innovations in D-Technical school on tap.

Outside Heart Updater: A auspicious sign came March 2, when Tandem announced it was finally ready to launch its Gimmick Updater that was approved by the FDA last summertime. This is a first in the insulin pump world, allowing a pump to be updated remotely from home, just like a smartphone can make up. Soon, anyone who bought a t:slim in front Apr 2015 (when new software features were built into those devices), can use this software updater to bring their older t:little pumps up to escort with the latest version of software. Tandem bicycle has also filed with the a submission FDA for approval to enjoyment this Remote Updater with its newfangled t:slight X2 platform for future CGM integrating (more on that under).

New Infusion Set Connecter: Ahead of Tandem bicycle's March 8 profits call the fellowship proclaimed plans to launch a new extract set connector dubbed the t:lock. For those naive in insulin pumps: This pump uses a Luer-Lock electron tube connector that's a universal design and works for virtually insulin pump models, except the proprietorship ones made for Medtronic pumps. Tandem offers four types of infusion sets (t:90, t:30, Solace, and Contact sets; the Cleo was phased out last year) and before the t:lock u you could use other Luer-Lock infusion sets. After the end of this year, anyone using t:slight pumps bequeath have to use extract sets that have this specific t:lock connector.

According to a Tandem spokesman, "The t:lock away connector is not actually proprietary — it has been utilized by other companies, for other therapies. Tandem has custom-made IT for use with our insulin pumps. The t:lock should not impact patient experience, and users will still be able to undergo supplies, either from distributors operating room Tandem directly. The Brobdingnagian absolute majority of users use the sets Tandem bicycle has always provided."

OK, the fact is you'll have to vex the sets directly from In tandem or a distributer and they must have this unique  t:lock connector… That's trademarked, folk. The selling materials describe this as being "supported straight-from-the-shoulder client feedback" and a helpful innovation that saves 4.5 units of insulin and cuts down the timing of pick the reservoir away more than 30 seconds. This will start rolling exterior in the coming months, and Tandem expects all customers to be switched over to use these t:lock connectors by year's end.

Dexcom Integration: Tandem has submitted to the FDA its integration with the Dexcom G5, allowing for the supra-mentioned Remote Updater to give pumpers admittance to G5 data directly along their t:small X2 devices. The company's preparing for a mid-2017 launch, and expects to comprise ready stupefy this on the market within 30 days of regulatory approval. Tandem also points out that anyone who purchases the Tandem t:svelte X2 before this favourable reception volition be able to update the CGM software at no more cost — something that indicates to U.S., at to the lowest degree, that Tandem may be preparation to charge otherwise customers to update their X2 devices for CGM functionality.

Unopen-Loop System: In tandem is working on its first automated insulin delivery organization, following a pre-submission group meeting with the FDA in December 2016 regarding pivotal trial development. Pentad trial sites have been determined and this National Institutes of Health-funded work is supposed to end by the end of October, meaning we could get a line a submission by year's end or early 2018 and peradventure a launch sometime future year. American Samoa detailed before, this first-gen system leave have a Predictive Low Glucose Freeze (PLGS) feature that would automatically close off insulin legal transfer when a hypo is predicted based happening the Dexcom CGM. For its 2d multiplication, Tandem plans to integrate an algorithm created away TypeZero Technologies for a "treat-to-target" system to align insulin doses to keep users continually aiming for a particular blood glucose identification number. That will expend the Dexcom G6, which will likely be visible starting close year. That is also expected by the cease of 2018.

Medtronic Diabetes

Medtronic held is every quarter earnings call on Feb. 21. While it didn't offer much update on their future word of mouth, the company's leadership was of course stirred about the coming launch of the Minimed 670G — the prototypic Crossbreed Closed-loop system that can mechanically sense glucose values based happening CGM readings, and adjust insulin radical doses accordingly to keep users in the locality of a pre-down 120 Mg/deciliter objective. While you still have to bolus for department of corrections and meals, this next-multiplication applied science that was FDA authorized in September 2016 has been more than a decade in the making and it's the first of many closed-loop system iterations to come, from Medtronic and beyond.

Happening March 6, Medtronic Diabetes announced that information technology was beginning a "staggered rollout" of the 670G. The company has been promising a Spring 2017 launch for months now, but it turns taboo that ISN't exactly the case for most citizenry interested in this D-tech. As an alternative, it will be at least June or later summer earlier most PWDs will have memory access to it, thanks to this additive launch plan:

  • Early March (now started): Begins with ~100 MedT employees World Health Organization are a subset of the larger Priority Access Program group, plus a small come of Wellness Care Practitioners (HCPs) who will follow early organization "testers." MedT is working to puzzle out the most different group to do a "dried-up-unravel" of these systems.
  • Middle to Late March: Will expand to slightly big group of external customers who are registered in their Anteriority Access code Program.
  • June: Launch to the entire Priority Get at Course of study radical.
  • End Summertime/Early Fall: Wax commercial launch in the U.S. for late and alive customers.

More details on the Priority Access Program and the company's 670G rollout can be found here. This is generating a great deal of buzz these days across the board in the diabetes device industry.

From sources away the recent earnings call, we know on that point's more just the Hybrid Closed Loop on the nigh-full term horizon.

Stand-Alone Tutelar Connect: We rumored on Medtronic's plans for a next-gen complete CGM system hinder in October 2014, and are now told the company has renamed it the Tutelary Link up (ordered with its Minimed Connect data-viewing political program, no doubt), and IT will use the selfsame Guardian 3 CGM sensor being unveiled with the 670G system. It's already been approved internationally, and is earlier the Food and Drug Administration for survey now. We pressed for more detail, just the company would only say the programme is to launch in past 2017 at one time it gets the FDA's nod.

Minimed 690G: We were excited to see coverage from the Advanced Technologies and Treatments for Diabetes (ATTD) event in France in February outlining the next-gen tech that MedT has in mind. Say hello to the Minimed 690G, a more fully automatic edition of the winking iteration we'ray now just starting to see launched Hera in the States. From what we saw of screen images, the form factor looks mostly the same as the 670G but information technology offers a fuzzy-logic algorithm that enables automatic bolusing, repast dosing and exercise input factored into the system. This is one of four closed loop systems being studied in the ongoing NIH-funded closed loop research (on with In tandem/TypeZero's InControl scheme, Beta Bionics' iLET, and the University of Cambridge research on the FlorenceM organization). As of now, in that location's no more timing on this merely we can assume it's slated for roughly 2020 if the R&D goes accordingly to plan.

Dexcom

The California-based CGM company held its quarterly earnings turn Feb. 28. While the Centers for Medicare and Medicaid Services (CMS) limited reportage decisiveness is a monumental stepping stone toward getting Medicare reportage for CGMs crossways the control panel, information technology hasn't yet materialized into a finalized process. Meanwhile, we're all pretty excited about the latest in the Dexcom's pipeline and its future tech plans:

  • Touchscreen Receiver: an upgraded translation of the current Dexcom Receiver wish improve along lastingness and speaker issues for alerts and alarms. Currently unfinished at the FDA.
  • G5x Vector: an upgrade to the G5 system that will be more covenant, and flush small than the previous G4 model. Currently pending at the FDA.
  • New One-Button Insertion Device: expected at some point mid-year. From prototype images we've seen, it appears to resemble the Medtronic Enlite sensor inserter that can be operated with cardinal hand. Currently pending at the FDA.
  • Updated G5 Mobile App: Dexcom has filed firmware updates to its iOS-compatible G5 app, which may include new features such as Insulin on Board (IOB) data as cured as other retrospective information analysis reports. The company is also awaiting regulatory OK for its Android-compatible version of the G5 app.
  • Next-generation G6 sensor: polar trial work for the close-generation G6 sensor continues, and Dexcom plans to file that with the FDA by the end of September. The end: Launch in early 2018. The G6 will be a true bound forward in CGM technical school, with 10 days of wear instead of the afoot 7, only one every day calibration required instead of two, and improved truth and reliability. Given how quickly the FDA has emotional on D-tech in recent years, we're positive!

Verily Quislingism: Dexcom is likewise continuing its process the first-generation technical school with Verily (formerly Google Life Sciences) that will be a miniaturized, dime-sized version of a CGM sensor that requires no calibration. Since IT's based on the G6 planned for set up in the starting time half of 2018 (depending on regulatory review), Dexcom hopes for commercialized at the end of '18. The second-generation is planned for roughly 2020 or 2021.

Share on Pinterest

Smart Insulin Pens: Interestingly, Dexcom also said on its earnings call that they're interested in exploring the smart insulin pen market — in particular on the heels of key clinical trial data showing the benefits of CGM for those on injections only, and non insulin pumps. "We're very bullish on the opportunity for smart pens," CEO Kevin Sayer said. "The real value in these systems leave be integration that insulin on board (IOB) information from a smart penitentiary, together with our CGM information, in a single unified app on the phone. We can do some pretty powerful stuff there. So, when you start demonstrating outcomes with a wise pen together with CGM data and providing patients with dosing support information, behavior modification information, genuinely, at a divide of the cost of some more convoluted systems, I retrieve we really cause a rest home run on that point."

We hope soh. As e'er, we can't wait to insure what's next from Dexcom.

Insulet

In its Feb. 28 earnings call, Boston-based OmniPod-maker Insulet highlighted its plans for 2017 after recapping the business goal from the past class. Largely, there weren't any updates on D-Tech that we haven't heard before:

  • OmniPod DASH: As we reported last Fall, the prominent news is Insulet's development of its next-gen, touch screen OmniPod DASH platform that will have a parvenue touchscreen PDM and Bluetooth-enabled Pod. That has not yet been submitted to the FDA from what we've heard, and even though Insulet says IT's now doing the clinical human factors cultivate on this device, it's still planning for a found former 2017. We expect to see this new platform on reveal at the Adenosine deaminase Scientific Sessions in June, and As of now the company's expecting a phased rollout that goes through the first few months of 2018.
  • Closed-Loop Technical school: Inchoate clinical work continues on Insulet's Horizon out of use loop technology, which will at first bring us a interbred closed grommet at some stage in late 2019 and eventually a much fully automatic closed loop system.
  • Access and Awareness: Insulet says it's as wel discussing Medicare coverage of OmiPod and expanding its sales and awareness efforts crosswise the U.S. during 2017. Later this twelvemonth, Podders can likewise expect to see an online patient portal for training on the patch pump too as an online resource for investigating both insurance benefits and financial assistance programs for OmniPod.

The Rest

Patc there wasn't a intact hatful of meaty stuff coming out of recent lucre calls from other players in the diabetes technical school earthly concern, there are a a couple of noteworthy nuggets worth sharing:

Abbott Diabetes: During the companion's late January remuneration call that it was expecting the FreeStyle Libre New York minute Glucose Monitoring (FGM) system to embody *last* become available in the U.S. sometime in the secondly half of 2017. The caller filed for approval mid-2015, and while the blinded professional version got regulatory headroom last Fall and is already procurable, the consumer rendering corpse pending with the FDA.

Roche: Hardly anything on diabetes was mentioned during this Pharma giant's Feb. 1 earnings call. Shut up, there's some D-intrigue close Roche. Following the company's decision to stop selling insulin pumps in the U.S. at the originate of 2017, its latest Accu-Chek Guide meter is still not available after getting favourable reception last summer; it's a bit of a head-scratcher as to what is taking auf wiedersehen on that one.

And updates from attendees of the big ATTD meeting in France in February show that Roche was showing off its own CGM organization under development that bequeath be called the Accu-Chek Insight CGM.

Share on Pinterest

Ploughshare on Pinterest

While that next product has been discussed and displayed for years now, thither appears to a lot of buzz now virtually Roche bringing it to the U.S. soon, and about more D-Tech partnerships with other companies. For example, Roche and Medtronic recently announced an exclusive deal to create a Bluetooth-enabled glucose measure that rear end be used with MedT pumps. And while naught's in time in ink, we also heard rumor recently that Roche could be talking with closed iteration startup Bigfoot Biomedical about future possibilities. We'll be keeping a close eye on the Roche equally the year progresses.

JnJ Diabetes Companies: We're all silence on the edge of our seats waiting to see what Johnson and Johnson decides to exercise with its Lifescan/ OneTouch /Animas diabetes tech brands. The company has announced publically that it's exploring strategies on the future of totally its diabetes business, with options ranging from restructuring to possibly selling unsatisfactory certain divisions. Hopefully, their umpteen diabetes tools that so many of us have come to trust on don't disappear.

And so D-peeps, any thoughts to share on every this new stuff coming down the throughway? Or anything to add?